BioAdvance News Portfolio News Relmada Therapeutics

Relmada Therapeutics Presents Clinical Data on Increased BDNF Plasma Levels in Subjects Treated with REL-1017

By WebmasterDecember 12, 2018November 1st, 2024No Comments

Relmada Therapeutics Presents Clinical Data on Increased BDNF Plasma Levels in Subjects Treated with REL-1017
Findings on Effect of REL-1017 on BDNF Plasma Levels Presented at Annual Meeting of the American College of Neuropsychopharmacology

See more here

Previous PostPalvella Therapeutics Announces $10 Million in Funding from Ligand Pharmaceuticals to Accelerate PTX-022 through Phase 2/3 Clinical Study in Pachyonychia Congenita
Next PostCEO of Group K Diagnostics Nominated to the Philadelphia Startup Leaders Board

Relmada Therapeutics Presents Clinical Data on Increased BDNF Plasma Levels in Subjects Treated with REL-1017

SEARCH

TOPICS

ARCHIVES

RECENT POSTS

Previous PostPalvella Therapeutics Announces $10 Million in Funding from Ligand Pharmaceuticals to Accelerate PTX-022 through Phase 2/3 Clinical Study in Pachyonychia Congenita

Next PostCEO of Group K Diagnostics Nominated to the Philadelphia Startup Leaders Board